Cristcot's Major Engagement at the 2025 GI ReConnect Annual Meeting
On June 24, 2025, Cristcot, a pioneering clinical-stage pharmaceutical company dedicated to innovative treatments for gastrointestinal diseases, marked its presence as a Gold Sponsor at the 5th annual GI ReConnect meeting held in Aurora, Colorado. This influential gathering brought together esteemed gastroenterologists from various academic institutions and community practices nationwide, all united to discuss the latest advancements in gastroenterology (GI) care.
Cristcot used this platform to facilitate an in-depth medical exchange session with leading GI experts to address current trends in ulcerative colitis (UC) treatment. The company spotlighted significant progress regarding its pivotal Phase 3 CESSA study, aimed at treating UC, receiving positive accolades from expert clinicians for its novel investigational hydrocortisone acetate (HCA) 90 mg suppository, delivered via the unique Sephure® applicator. This delivery innovation is designed to minimize discomfort during administration, which may enhance patient adherence to the treatment regimen.
CEO Jennifer J. Davagian expressed her excitement about Cristcot's engagement at the conference, emphasizing the importance of collaboration with gastroenterology professionals. "We were thrilled to sponsor this year’s GI ReConnect and continue to receive support from esteemed colleagues and thought leaders in gastroenterology on our efforts to address the needs of UC patients," she stated. The company is currently riding a wave of momentum focused on advancing its late-stage UC program while nurturing deep partnerships within the GI community.
Dr. Raj Devarajan, Cristcot's Global Medical Advisor, elaborated on the value of such forums for real-time dialogue between therapy developers and physicians. "Hearing firsthand from leading gastroenterologists about trends in UC care provides essential insights that will inform and strengthen our clinical strategies. This ensures we’re aligned with the latest developments and truly focused on meeting the needs of patients requiring new solutions,” he remarked.
Cristcot’s participation in the GI ReConnect meeting is a part of its larger vision to broaden its footprint in the gastroenterology sector. The company is also planning to attend several additional GI-focused scientific gatherings throughout 2025, further establishing its commitment to innovation in this vital medical field.
About Cristcot's HCA 90 mg Suppository
The HCA 90 mg suppository from Cristcot represents a groundbreaking approach in the treatment landscape for UC. Using the Sephure® applicator, this small-volume suppository guarantees precise placement while minimizing discomfort and leakage – key factors that enhance patient compliance. Unlike conventional corticosteroid treatments, its distinctive action mechanism facilitates rapid release and localized effects, which helps in reducing systemic exposure and potential side effects.
Understanding Ulcerative Colitis
Ulcerative colitis manifests as a chronic autoimmune disorder, characterized by inflammation and ulceration in the lining of the large intestine, including the rectal area, and potentially extending throughout the colon. Patients frequently contend with symptoms such as rectal bleeding, intense diarrhea, urgent bowel movements, tenesmus, and abdominal discomfort—conditions that significantly diminish their quality of life. Flare-ups of UC, which may arise suddenly, often lead to important health implications, such as hospitalization or surgical interventions. Unfortunately, there's currently no definitive cure for the condition, and even those on maintenance medication experience unexpected flare-ups.
Statistics indicate that over 55% of UC patients undergo three to five flare-ups annually, adversely affecting daily routines, work performance, and mental well-being. Moreover, the transition between therapies during flare-ups is complicated, as patients often have to wait for new treatments to achieve their full efficacy potential. This highlights the vital need for targeted therapies that can yield rapid symptom relief and induce remission.
About Cristcot
Headquartered in Concord, Massachusetts, Cristcot is a clinical-stage pharmaceutical company on a mission to innovate treatments for gastrointestinal diseases. Its flagship asset, a novel hydrocortisone acetate suppository, is strategically positioned to become the first-line therapy option for ulcerative colitis management. Along with UC, Cristcot's diverse pipeline includes investigational medications for acute pancreatitis, hemorrhoidal disease, and various inflammatory gastrointestinal conditions, emphasizing solutions centered around patient needs. For further insights, connect with Cristcot on
www.cristcot.com and engage with them on LinkedIn.